Breaking News Instant updates and real-time market news.

IOVA

Iovance Biotherapeutics

$8.80

-0.66 (-6.98%)

16:26
11/06/18
11/06
16:26
11/06/18
16:26

Iovance says patient dosing continues in C-145-04 study

Iovance Biotherapeutics said in today's earnings release, "Patient dosing continues in the C-145-04 study for cervical carcinoma. The company recently dosed its first patient in Europe. This study design is based on a Simon's two-stage design. The first stage has been completed and enrollment in the study continues with target enrollment of 47. Preliminary data for 15 patients yielded an ORR of 27% with an early look at the DOR ranging from 2.4 to 2.5+ months. Patients in the study had a median of five prior therapies. The safety findings from this study remain consistent with previous reports. The protocol for this study has been amended to limit the number of prior therapies to no more than three and to exclude patients who have been treated with prior immunotherapy. Iovance anticipates providing an update on this study at an upcoming medical meeting in 2019. In the C-145-03 study for head and neck cancer, to date, preliminary data for 13 patients has yielded an ORR of 31% with the DOR ranging from 2.8 to 7.6 months. The safety findings from this study is also consistent with previous reports. Patients in the study had a median of three prior therapies. For the study in NSCLC, IOV-LUN-201, in collaboration with MedImmune, the company amended the protocol to eliminate the TIL monotherapy cohort and patients will now be enrolled for treatment with LN-145 and durvalumab. There are currently nine sites active for this trial. The study in PD-1 naive melanoma and head and neck patients with TIL in combination with pembrolizumab, and LN-145 as monotherapy in NSCLC patients (IOV-COM-202) is open to enrollment with two sites active."

  • 06

    Nov

  • 20

    Nov

IOVA Iovance Biotherapeutics
$8.80

-0.66 (-6.98%)

11/06/18
WELS
11/06/18
NO CHANGE
WELS
Outperform
Iovance data supportive of potential approval, says Wells Fargo
The 38% response rate and duration greater than six months seen in this morning's abstract data for tumor-infiltrating lymphocyte therapeutic lifleucel in PD1 experienced metastatic melanoma are "highly differentiated from other cell therapies in solid tumors and supportive of potential approval if confirmed by pivotal study," Wells Fargo analyst Jim Birchenough tells investors in a research note. The analyst keeps an Outperform rating on shares of Iovance Biotherapeutics. The stock in morning trading is down 10%, or 99c, to $8.46.
10/12/18
HCWC
10/12/18
NO CHANGE
HCWC
Iovance Biotherapeutics price target raised to $26 from $22 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Iovance Biotherapeutics and raised his price target on shares to $26 from $22, following the outcome of the end-of-Phase 2 meeting with the FDA regarding lead candidate LN-144. Pantginis called the interactions with the FDA "successful," and believes that Iovance will "further pursue its discussion with the agency in order to find the best path forward for LN-144 followed by assets across multiple indications." Additionally, the analyst reiterated his belief that Iovance is a compelling takeout candidate, and added that the company's cash resources provide strong leverage in any discussions.
10/12/18
OPCO
10/12/18
NO CHANGE
Target $25
OPCO
Outperform
Iovance Biotherapeutics price target raised to $25 from $22 at Oppenheimer
Oppenheimer analyst Mark Breidenbach reiterated an Outperform rating on Iovance Biotherapeutics and raised his price target to $25 from $22 citing recent positive clinical updates for its tumor infiltrating lymphocyte product for melanoma and the outcome of discussions with the FDA regarding the regulatory pathway forward.
09/25/18
COWN
09/25/18
NO CHANGE
COWN
Outperform
Iovance Biotherapeutics weakness a buying opportunity, says Cowen
Cowen analyst Boris Peaker said the recent weakness in Iovance is a buying opportunity. The analyst noted the company's results from the Moffitt-run study of TILS in NSCLC were deemed mild and somewhat disappointing. He believes the data has no read-through to the ongoing melanoma trial, making the weakness an attractive entry point. Peaker reiterated his Outperform rating on Iovance shares.

TODAY'S FREE FLY STORIES

01:45
11/16/18
11/16
01:45
11/16/18
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

VIAB

Viacom

$31.87

0.07 (0.22%)

, VIA

Viacom

$36.09

0.76 (2.15%)

20:25
11/15/18
11/15
20:25
11/15/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

VIAB

Viacom

$31.87

0.07 (0.22%)

VIA

Viacom

$36.09

0.76 (2.15%)

HP

Helmerich & Payne

$60.05

1.75 (3.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

  • 16

    Nov

  • 16

    Nov

  • 04

    Dec

TECK

Teck Resources

$22.04

0.9 (4.26%)

20:23
11/15/18
11/15
20:23
11/15/18
20:23
Hot Stocks
Teck Resources announces $400M stock buyback »

Teck Resources Board has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIX

Edison International

$47.07

-6.84 (-12.69%)

20:22
11/15/18
11/15
20:22
11/15/18
20:22
Hot Stocks
Edison International provides update on California fire restoration efforts »

Southern California…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLRX

Valeritas

$0.47

-0.18 (-27.67%)

20:20
11/15/18
11/15
20:20
11/15/18
20:20
Syndicate
Valeritas 75M share Secondary priced at $0.48 »

Valeritas Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVMXY

Avita Medical

$0.00

(0.00%)

20:06
11/15/18
11/15
20:06
11/15/18
20:06
Hot Stocks
Avita Medical to hire U.S. sales team to support national launch of Recell »

AVITA Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SDXAY

Sodexo

$0.00

(0.00%)

20:05
11/15/18
11/15
20:05
11/15/18
20:05
Downgrade
Sodexo rating change at JPMorgan »

Sodexo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CATY

Cathay General

$38.83

0.91 (2.40%)

20:01
11/15/18
11/15
20:01
11/15/18
20:01
Hot Stocks
Cathay General raises quarterly dividend to 31c from 24c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

SUPV

Grupo Supervielle

$8.50

0.42 (5.20%)

19:56
11/15/18
11/15
19:56
11/15/18
19:56
Downgrade
Grupo Supervielle rating change at Santander »

Grupo Supervielle…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAAP

Corporacion America Airport

$8.37

0.63 (8.14%)

19:52
11/15/18
11/15
19:52
11/15/18
19:52
Hot Stocks
Corporacion America Airport reports October traffic up 4.5% »

Corporacion America…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$348.37

4.3 (1.25%)

19:43
11/15/18
11/15
19:43
11/15/18
19:43
Periodicals
Tesla aims for Model 3 output of 7K units per week in two weeks, Electrek says »

Tesla has looked to ramp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 13

    Dec

AIV

Aimco

$44.65

-0.46 (-1.02%)

19:26
11/15/18
11/15
19:26
11/15/18
19:26
Hot Stocks
Aimco says California fires have not caused material damage to company »

Apartment Investment and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$239.93

4.83 (2.05%)

19:19
11/15/18
11/15
19:19
11/15/18
19:19
Initiation
Adobe initiated at Nomura Instinet »

Nomura starts Adobe with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPWR

Ideal Power

$0.39

-0.1505 (-27.87%)

19:16
11/15/18
11/15
19:16
11/15/18
19:16
Downgrade
Ideal Power rating change at Oppenheimer »

Ideal Power downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

SONO

Sonos

$14.14

0.17 (1.22%)

, SCVL

Shoe Carnival

$37.03

-1.94 (-4.98%)

19:09
11/15/18
11/15
19:09
11/15/18
19:09
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Sonos…

SONO

Sonos

$14.14

0.17 (1.22%)

SCVL

Shoe Carnival

$37.03

-1.94 (-4.98%)

BGCP

BGC Partners

$10.66

0.24 (2.30%)

SALT

Scorpio Bulkers

$5.71

0.115 (2.06%)

ESEA

Euroseas

$1.65

-0.11 (-6.25%)

NVDA

Nvidia

$202.65

5.43 (2.75%)

WSM

Williams-Sonoma

$60.60

-1.16 (-1.88%)

JWN

Nordstrom

$58.97

-2.125 (-3.48%)

AMAT

Applied Materials

$35.03

1.44 (4.29%)

HTHT

Huazhu Group

$28.59

0.64 (2.29%)

SQ

Square

$73.59

3.74 (5.35%)

NGVC

Natural Grocers

$16.66

0.06 (0.36%)

MCF

Contango Oil & Gas

$4.50

-0.19 (-4.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 16

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

  • 12

    Dec

  • 18

    Dec

DOMO

Domo

$15.96

0.47 (3.03%)

19:04
11/15/18
11/15
19:04
11/15/18
19:04
Hot Stocks
Domo unveils new product suite »

Domo, provider of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PCH

PotlatchDeltic

$36.71

-0.31 (-0.84%)

19:01
11/15/18
11/15
19:01
11/15/18
19:01
Hot Stocks
PotlatchDeltic to pay special dividend of about $3.54 per share »

PotlatchDeltic announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$143.86

-0.39 (-0.27%)

18:54
11/15/18
11/15
18:54
11/15/18
18:54
Periodicals
Senator to ask Facebook about report on treatment of critics, Reuters says »

Senator Amy Klobuchar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

ALRM

Alarm.com

$48.81

0.82 (1.71%)

18:45
11/15/18
11/15
18:45
11/15/18
18:45
Hot Stocks
Alarm.com CEO sells 30K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 26

    Nov

  • 05

    Dec

LAUR

Laureate Education

$14.45

0.3 (2.12%)

18:31
11/15/18
11/15
18:31
11/15/18
18:31
Syndicate
Laureate Education 12.25M share Secondary priced at $14.00 »

Credit Suisse, Barclays,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

PCG

PG&E

$17.77

-7.89 (-30.75%)

18:28
11/15/18
11/15
18:28
11/15/18
18:28
Periodicals
CPUC doesn't want PG&E to go into bankruptcy, Bloomberg says »

A California Public…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTC

Bitcoin

$0.00

(0.00%)

, BITCOIN

Bitcoin

$0.00

(0.00%)

18:24
11/15/18
11/15
18:24
11/15/18
18:24
Periodicals
SEC investigating a company's $50M cryptocurrency sale, WSJ reports »

The SEC is investigating…

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$17.77

-7.89 (-30.75%)

18:23
11/15/18
11/15
18:23
11/15/18
18:23
Hot Stocks
PG&E cut to Baa3 from Baa2 by Moody's, could be cut further »

Moody's downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMB

Limbach Holding

$8.31

-0.14 (-1.66%)

18:10
11/15/18
11/15
18:10
11/15/18
18:10
Hot Stocks
Limbach Holding lowers FY18 EBITDA view to $8M-$10M from $18M-$20M »

Backs FY18 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

NVDA

Nvidia

$202.65

5.43 (2.75%)

18:08
11/15/18
11/15
18:08
11/15/18
18:08
Hot Stocks
Nvidia CEO says the ramp of Turing GPU is 'going great' »

Says Turing represents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.